These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 26475289

  • 21. Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis.
    Igase M, Kohara K, Tabara Y, Ohara M, Takita R, Ochi M, Okada Y, Miki T.
    Menopause; 2014 Sep; 21(9):962-6. PubMed ID: 24552979
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH.
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
    [Abstract] [Full Text] [Related]

  • 24. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
    Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T.
    Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
    Frost ML, Siddique M, Blake GM, Moore AE, Marsden PK, Schleyer PJ, Eastell R, Fogelman I.
    Osteoporos Int; 2012 Aug; 23(8):2107-16. PubMed ID: 21983795
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD, Epstein S, Sedarati F, Reginster JY.
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [Abstract] [Full Text] [Related]

  • 34. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
    Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM, Fracture Intervention Research Group.
    J Bone Miner Res; 2006 Feb; 21(2):292-9. PubMed ID: 16418785
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 37. A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
    Yoshioka T, Okimoto N, Okamoto K, Sakai A.
    J Bone Miner Metab; 2013 Mar; 31(2):153-60. PubMed ID: 23076293
    [Abstract] [Full Text] [Related]

  • 38. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y, Suzuki T, Kato H.
    Arch Osteoporos; 2017 Sep 21; 12(1):80. PubMed ID: 28936606
    [Abstract] [Full Text] [Related]

  • 39. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M, Tuzun C, Unlu Z, Tikiz C, Taneli F, Uyanik BS.
    Rheumatol Int; 2006 Jan 21; 26(3):195-200. PubMed ID: 15580349
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.